NLS Pharmaceutics Ltd. (NLS) Files Registration Statement for a Proposed Initial Public Offering
March 02, 2020 09:00 ET
|
NLS Pharmaceutics
STANS, Switzerland, March 02, 2020 (GLOBE NEWSWIRE) -- NLS Pharmaceutics Ltd. (NLS), a Swiss biotech firm focusing on the development of novel treatments of rare neurological diseases including...
NLS Pharmaceutics Ltd. Announces Notice of Allowance of a new U.S. Patent Covering Attention Deficit Hyperactivity Disorder strengthening the scope of NLS’ Patent Portfolio
September 30, 2019 10:00 ET
|
NLS Pharmaceutics
STANS, Switzerland, Sept. 30, 2019 (GLOBE NEWSWIRE) -- NLS Pharmaceutics Ltd. (NLS), a Swiss biotech firm focusing on the development of novel treatments of rare neurological diseases including...
NLS Announces Appointment of Industry Veteran Dr. Sandy Eisen as Chief Medical Officer
September 03, 2019 08:00 ET
|
NLS Pharmaceutics
STANS, Switzerland, Sept. 03, 2019 (GLOBE NEWSWIRE) -- NLS Pharmaceutics Ltd. (NLS), a Swiss biotech firm focusing on the development of novel treatments of rare neurological diseases, including...
NLS Pharmaceutics Ltd. (NLS) Announces a Reexamination Certificate by the USPTO Further Strengthening their ADHD Use Patent Validity
August 13, 2019 13:04 ET
|
NLS Pharmaceutics
STANS, Switzerland, Aug. 13, 2019 (GLOBE NEWSWIRE) -- NLS Pharmaceutics Ltd. (NLS), a Swiss biotech firm focusing on the development of novel treatments of rare neurological diseases including...
NLS Pharmaceutics Ltd. (NLS) Announces Notice of Allowance of two new Patents in North America Covering Attention Deficit Hyperactivity Disorder (ADHD) and Narcolepsy further bolstering its Patent Portfolio
July 03, 2019 09:00 ET
|
NLS Pharmaceutics
STANS, Switzerland, July 03, 2019 (GLOBE NEWSWIRE) -- NLS Pharmaceutics Ltd. (NLS), a Swiss biotech firm focusing on the development of novel treatments for the Central Nervous System (CNS) in...
NLS Pharmaceutics Announces the Completion of the Merger between NLS Pharma Ltd., NLS-1 Pharma Ltd. and NLS-0 Pharma, Unifying the Global Operations and Development of Nolazol®
March 19, 2019 16:05 ET
|
NLS Pharmaceutics
STANS, Switzerland, March 19, 2019 (GLOBE NEWSWIRE) -- NLS Pharmaceutics Ltd (NLS), a Swiss biotech firm focusing on the development of novel treatments for Attention-Deficit/Hyperactivity Disorder...
NLS-1 Pharma and Eurofarma Enter to an Exclusive Licensing Agreement to Develop and Commercialize Nolazol® for the Treatment of ADHD in Latin America
February 21, 2019 08:00 ET
|
NLS-1 Pharma AG
STANS, Switzerland, Feb. 21, 2019 (GLOBE NEWSWIRE) -- NLS-1 Pharma (NLS), a Swiss biotech firm focusing on the development of novel treatments for Attention-Deficit/Hyperactivity Disorder (ADHD) and...